234.94 0.00 (0.00%)
After hours: 4:48PM EST
|Bid||234.75 x 1300|
|Ask||234.74 x 800|
|Day's Range||233.84 - 237.70|
|52 Week Range||107.44 - 242.14|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||245.25|
Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.
As Intuitive Surgical and InMode lead the medical equipment industry, diabetes innovator Dexcom is right there with them — and set to retry a new breakout.
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
AmerisourceBergen's (ABC) Q1 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.
Dexcom Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for February 13, 2020 at 4:30 p.m. Eastern Time
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.